|
1
|
Miller KD, Siegel RL, Lin CC, Mariotto AB,
Kramer JL, Rowland JH, Stein KD, Alteri R and Jemal A: Cancer
treatment and survivorship statistics, 2016. CA Cancer J Clin.
66:271–289. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Akram M, Iqbal M, Daniyal M and Khan AU:
Awareness and current knowledge of breast cancer. Biol Res.
50:332017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Aumeeruddy MZ and Mahomoodally MF:
Combating breast cancer using combination therapy with 3
phytochemicals: Piperine, sulforaphane, and thymoquinone. Cancer.
125:1600–1611. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shamsi U, Khan S, Usman S, Soomro S and
Azam I: A multicenter matched case control study of breast cancer
risk factors among women in Karachi, Pakistan. Asian Pac J Cancer
Prev. 14:183–188. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zainal NZ, Nik-Jaafar NR, Baharudin A,
Sabki ZA and Ng CG: Prevalence of depression in breast cancer
survivors: A systematic review of observational studies. Asian Pac
J Cancer Prev. 14:2649–2656. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Shaukat U, Ismail M and Mehmood N:
Epidemiology, major risk factors and genetic predisposition for
breast cancer in the Pakistani population. Asian Pac J Cancer Prev.
14:5625–5629. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Han G, Qiu N, Luo K, Liang H and Li H:
Downregulation of miroRNA-141 mediates acquired resistance to
trastuzumab and is associated with poor outcome in breast cancer by
upregulating the expression of ERBB4. J Cell Biochem. Feb
11–2019.(Epub ahead of print).
|
|
9
|
Wu H, Tao J, Li X, Zhang T, Zhao L, Wang
Y, Zhang L, Xiong J, Zeng Z, Zhan N, et al: MicroRNA-206 prevents
the pathogenesis of hepatocellular carcinoma by modulating
expression of met proto-oncogene and cyclin-dependent kinase 6 in
mice. Hepatology. 66:1952–1967. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sun KK, Shen XJ, Yang D, Gan MQ, Liu G,
Zhang YF, Hua P, Wang HD and Wu XY: MicroRNA-31 triggers G2/M cell
cycle arrest, enhances the chemosensitivity and inhibits migration
and invasion of human gastric cancer cells by downregulating the
expression of zeste homolog 2 (ZH2). Arch Biochem Biophys.
663:269–275. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Xu L, Feng X, Hao X, Wang P, Zhang Y,
Zheng X, Li L, Ren S, Zhang M and Xu M: CircSETD3
(Hsa_circ_0000567) acts as a sponge for microRNA-421 inhibiting
hepatocellular carcinoma growth. J Exp Clin Cancer Res. 38:982019.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yang Y, Ishak Gabra MB, Hanse EA, Lowman
XH, Tran TQ, Li H, Milman N, Liu J, Reid MA, Locasale JW, et al:
miR-135 suppresses glycolysis and promotes pancreatic cancer cell
adaptation to metabolic stress by targeting phosphofructokinase-1.
Nat Commun. 10:8092019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ramalho S, Andrade LAA, Filho CC, Natal
RA, Pavanello M, Ferracini AC, Sallum LF, Sarian LO and Derchain S:
Role of discoidin domain receptor 2 (DDR2) and microRNA-182 in
survival of women with high-grade serous ovarian cancer. Tumour
Biol. 41:10104283188239882019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ding Z, Zhu J, Zeng Y, Du W, Zhang Y, Tang
H, Zheng Y, Qin H, Liu Z and Huang JA: The regulation of Neuropilin
1 expression by miR-338-3p promotes non-small cell lung cancer via
changes in EGFR signaling. Mol Carcinog. 58:1019–1032. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ren L, Chen H, Song J, Chen X, Lin C,
Zhang X, Hou N, Pan J, Zhou Z, Wang L, et al: miR-454-3p-mediated
Wnt/β-catenin signaling antagonists suppression promotes breast
cancer metastasis. Theranostics. 9:449–465. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liolios T, Kastora SL and Colombo G:
MicroRNAs in female malignancies. Cancer Inform.
18:11769351198287462019. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wu Y, Shi W, Tang T, Wang Y, Yin X, Chen
Y, Zhang Y, Xing Y, Shen Y, Xia T, et al: miR-29a contributes to
breast cancer cells epithelial-mesenchymal transition, migration,
and invasion via down-regulating histone H4K20 trimethylation
through directly targeting SUV420H2. Cell Death Dis. 10:1762019.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jiang J, Yang X, He X, Ma W, Wang J, Zhou
Q, Li M and Yu S: MicroRNA-449b-5p suppresses the growth and
invasion of breast cancer cells via inhibiting CREPT-mediated
Wnt/beta-catenin signaling. Chem Biol Interact. 302:74–82. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Abdelmohsen K, Srikantan S, Kuwano Y and
Gorospe M: miR-519 reduces cell proliferation by lowering
RNA-binding protein HuR levels. Proc Natl Acad Sci USA.
10:20297–20302. 2008. View Article : Google Scholar
|
|
20
|
Yu G, Zhang T, Jing Y, Bao Q, Tang Q and
Zhang Y: miR-519 suppresses nasopharyngeal carcinoma cell
proliferation by targeting oncogene URG4/URGCP. Life Sci.
175:47–51. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Michelle H..Howell A and Evans DG: Can
diet and lifestyle prevent breast cancer: What is the evidence. Am
Soc Clin Oncol Educ Bool. e66–e73. 2015.
|
|
23
|
Baretta Z, Mocellin S, Goldin E, Olopade
OI and Huo D: Effect of BRCA germline mutations on breast cancer
prognosis: A systematic review and meta-analysis.
Medicine(Baltimore). 95:e49752016.PubMed/NCBI
|
|
24
|
Lacerda JZ, Ferreira LC, Lopes BC,
Aristizábal-Pachón AF, Bajgelman MC, Borin TF and Zuccari DAPC:
Therapeutic potential of melatonin in the regulation of miR-148a-3p
and angiogenic factors in breast cancer. Microrna. 8:237–247. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hu D, Li M, Su J, Miao K and Qiu X:
Dual-targeting of miR-124-3p and ABCC4 promotes sensitivity to
adriamycin in breast cancer cells. Genet Test Mol Biomarkers.
23:156–165. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Oztemur Islakoglu Y, Noyan S and Gur
Dedeoglu B: hsa-miR-301a- and SOX10-dependent miRNA-TF-mRNA
regulatory circuits in breast cancer. Turk J Biol. 42:103–112.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Abdelmohsen K, Srikantan S, Tominaga K,
Kang MJ, Yaniv Y, Martindale JL, Yang X, Park SS, Becker KG,
Subramanian M, et al: Growth inhibition by miR-519 via multiple
p21-inducing pathways. Mol Cell Biol. 32:2530–2548. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lv Z, He K, Shi L, Shi K, Jiang T and Chen
Y: Interaction between C2ORF68 and HuR in human colorectal cancer.
Oncol Rep. 41:1918–1928. 2019.PubMed/NCBI
|
|
29
|
Kakuguchi W, Nomura T, Kitamura T,
Otsuguro S, Matsushita K, Sakaitani M, Maenaka K and Tei K:
Suramin, screened from an approved drug library, inhibits HuR
functions and attenuates malignant phenotype of oral cancer cells.
Cancer Med. 7:6269–6280. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Grammatikakis I, Abdelmohsen K and Gorospe
M: Posttranslational control of HuR function. Wiley Interdiscip Rev
RNA. 8:Jun 16–2017.(Epub ahead of print). doi: 10.1002/wrna.1372.
View Article : Google Scholar
|
|
31
|
Ko CY, Wang WL, Li CF, Jeng YM, Chu YY,
Wang HY, Tseng JT and Wang JM: IL-18-induced interaction between
IMP3 and HuR contributes to COX-2 mRNA stabilization in acute
myeloid leukemia. J Leukoc Biol; 99. pp. 131–141. 2016, PubMed/NCBI
|
|
32
|
Lafarga V, Cuadrado A, Lopez de Silanes I,
Bengoechea R, Fernandez-Capetillo O and Nebreda AR: p38
mitogen-activated protein kinase- and HuR-dependent stabilization
of p21(Cip1) mRNA mediates the G(1)/S checkpoint. Mol Cell Biol.
9:4341–4351. 2009. View Article : Google Scholar
|
|
33
|
Ghosh U and Adhya S: Posttranscriptional
regulation of cyclin D1 by ARE-binding proteins AUF1 and HuR in
cycling myoblasts. J Biosci. 43:685–691. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhu Z, Zhao Y, Li J, Tao L, Shi P, Wei Z,
Sheng X, Shen D, Liu Z, Zhou L, et al: Cryptotanshinone, a novel
tumor angiogenesis inhibitor, destabilizes tumor necrosis factor-α
mRNA via decreasing nuclear-cytoplasmic translocation of
RNA-binding protein HuR. Mol Carcinog. 55:1399–1410. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Mukherjee J, Ohba S, See WL, Phillips JJ,
Molinaro AM and Pieper RO: PKM2 uses control of HuR localization to
regulate p27 and cell cycle progression in human glioblastoma
cells. Int J Cancer. 139:99–111. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ghisolfi L, Calastretti A, Franzi S, Canti
G, Donnini M, Capaccioli S, Nicolin A and Bevilacqua A: B cell
lymphoma (Bcl)-2 protein is the major determinant in bcl-2
adenine-uridine-rich element turnover overcoming HuR activity. J
Biol Chem. 284:20946–20955. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ishimaru D, Ramalingam S, Sengupta TK,
Bandyopadhyay S, Dellis S, Tholanikunnel BG, Fernandes DJ and
Spicer EK: Regulation of Bcl-2 expression by HuR in HL60 leukemia
cells and A431 carcinoma cells. Mol Cancer Res. 7:1354–1366. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ruefli-Brasse A and Reed JC: Therapeutics
targeting Bcl-2 in hematological malignancies. Biochem J.
474:3643–3657. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Pan LL, Wang AY, Huang YQ, Luo Y and Ling
M: Mangiferin induces apoptosis by regulating Bcl-2 and Bax
expression in the CNE2 nasopharyngeal carcinoma cell line. Asian
Pac J Cancer Prev. 15:7065–7068. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Teijido O and Dejean L: Upregulation of
Bcl2 inhibits apoptosis-driven BAX insertion but favors BAX
relocalization in mitochondria. FEBS Lett. 584:3305–3310. 2010.
View Article : Google Scholar : PubMed/NCBI
|
